Abivax SA American Depositary Shares Stock (NASDAQ:ABVX)

Forecast Financials Chart Transcripts

Previous Close

$7.80

52W Range

$7.11 - $17.02

50D Avg

$9.39

200D Avg

$12.20

Market Cap

$497.19M

Avg Vol (3M)

$133.22K

Beta

1.42

Div Yield

-

ABVX Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

62

IPO Date

Oct 20, 2023

Website

ABVX Performance

ABVX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	$37.00K
Operating Income	$-132.00M	$-56.65M	$-42.56M
Net Income	$-147.40M	$-69.85M	$-41.36M
EBITDA	$-279.40M	$-56.45M	$-42.38M
Basic EPS	$-2.35	$-3.13	$-2.47
Diluted EPS	$-2.35	$-3.13	$-2.47

Fiscal year ends in Dec 23 | Currency in EUR

Latest Earnings Call Transcripts

Q4 23Apr 08, 24 | 1:25 PM